SERETIDE ® is a drug based on Salmeterol xinafoate and Fluticasone propionate.
THERAPEUTIC GROUP: Adrenergics for aerosols and other antihistamines
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications SERETIDE ® - Salmeterol and Fluticasone
SERETIDE ® is indicated in the treatment of asthma in patients requiring long-term therapy with corticosteroids and Beta 2 Agonists.
Mechanism of action SERETIDE ® - Salmeterol and Fluticasone
SERETIDE ® is a medicinal specialty that combines two active ingredients that have always been used in the treatment of asthma and chronic obstructive airway diseases, such as a corticosteroid and a beta 2 agonist.
The first, Fluticasone, is a corticosteroid particularly active by inhalation, able to reduce the secretion of inflammatory mediators, controlling the intracellular pathway, supported by Phospholipase A2, useful for the synthesis of prostaglandins, thromboxanes and leukotrienes.
All this takes the form of a reduction in the local phlogistic stimulus and a clear improvement in the congestive symptoms associated with this condition.
Salmeterol instead, a selective beta 2 adrenergic receptor agonist, is a molecule with an intense bronchodilator activity, thanks to the ability to bind and activate Beta 2 adrenergic receptors expressed by bronchial smooth muscle, guaranteeing a prolonged action in the time necessary to restore the normal ventilatory capacity.
The proportion of active ingredients occasionally absorbed systemically, following a hepatic metabolism, will be subsequently eliminated via the kidney.
Studies carried out and clinical efficacy
SERETIDE, ASTHMA AND GENES
Eur Rev Med Pharmacol Sci. 2012 Nov; 16 (12): 1701-6.
Interesting study that aims to evaluate the molecular mechanisms characterizing the asthmatic pathology, also taking care to characterize the potential therapeutic effect of the Seretide against these genetic and molecular pathways. The study focuses on the evaluation of over 400 genes and the relative molecular cascades in which they are involved.
SALMETEROL AND FLUTICASONE IN ASMATIC SMOKING PATIENTS
Chest. 2012 Feb; 141 (2): 330-8. doi: 10.1378 / chest.11-0392. Epub 2011 Jun 2.
An interesting study that demonstrates how the combined treatment with Salmeterol and Fluticasone can optimize the therapeutic response in asthmatic and smoking patients, also guaranteeing an important action against bronchial smooth muscles, generally contracted in smoking patients.
FLUTICASONE / SALMETEROL IN PATIENTS WITH COPD
Respir Med. 2013 May; 107 (5): 708-16. doi: 10.1016 / j.rmed.2013.01.009. Epub 2013 Feb 17.
Work carried out on patients suffering from chronic obstructive pulmonary disease which demonstrates that treatment for only 6 weeks with Fluticasone and Salmeterol can determine a clear improvement in symptoms, in particular dyspnea and respiratory difficulty during endurance exercise.
Method of use and dosage
SERETIDE ®
Pressurized suspension for inhalation from 25 mcg of Salmeterol and 50, 125 and 250 mcg of Fluticasone proprionate for delivery.
SERETIDE ® therapy must necessarily be defined and supervised by your doctor, due to the complexity and the enormous interindividual variability.
In fact, after carefully evaluating the patient's state of health and the severity of his clinical picture, the doctor should identify the minimum effective dose to guarantee a remission of symptoms.
Therefore, although the recommended doses in adults are those of two inhalations per day, it is not possible to define a recommendable and effective standard dosage for everyone.
Warnings SERETIDE ® - Salmeterol and Fluticasone
Therapy with SERETIDE ® must necessarily be preceded by a careful medical examination in order to clarify the origin of the complained symptomatology and the consequent prescriptive appropriateness, and be subsequently supervised both in terms of clinical efficacy and safety of use.
However, it is advisable for the doctor to define together with the basic therapy with SERETIDE ® also an emergency therapy in case of acute, clinically very significant asthmatic attacks.
Like other topical corticosteroid therapies, even with SERETIDE ®, especially if prolonged over time, could lead to the occurrence of local, more frequently, and rarely systemic, adverse reactions, such as hyperglycemia or alterations of the hypothalamic-pituitary axis adrenal gland.
Treatment with SERETIDE ® should be carried out with particular caution in patients suffering from renal pathologies, diabetes, hypertension, cardiovascular pathologies and viral, fungal or tuberculosis infections.
The use of SERETIDE ®, without clinical necessity, is prohibited in and out of the race.
It is recommended to keep the medicine out of the reach of children.
PREGNANCY AND BREASTFEEDING
From the moment in which the experimental evidences related to the use of these active ingredients in pregnancy and during breastfeeding are still quite controversial, it would be correct to extend the aforementioned contraindications to the use of SERETIDE ® also to pregnancy and the subsequent period of breastfeeding at the breast.
In these cases, the use of this drug should be justified only by real clinical needs and periodically supervised by your doctor.
Interactions
Although the systemic absorption of the two active ingredients is pharmacologically negligible, it would be appropriate for the patient on SERETIDE ® therapy to avoid the simultaneous intake of inhibitors or inducers of the cytochromial system, potentially responsible for significant alterations of the pharmacokinetic characteristics of the absorbed share of Fluticasone and Salmeterol .
It is also recommended to avoid the simultaneous intake of Beta blockers and Beta adrenergics.
Contraindications SERETIDE ® - Salmeterol and Fluticasone
The use of SERETIDE ® is contraindicated in patients with hypersensitivity to the active ingredient or to one of its excipients or to structurally and chemically related molecules.
Undesirable effects - Side effects
Therapy with SERETIDE ® could lead to the appearance of candidiasis of the mouth and throat, pneumonia, bronchitis, hypokalemia, nasopharyngitis, hoarseness, sinusitis, arthralgia and myalgia.
The incidence of the aforementioned side effects, accompanied by the possible incidence of other adverse reactions, would require the maximum precaution in using the drug.
Note
SERETIDE ® is a prescription-only drug.
